GLP-1 receptor agonists were originally developed to treat diabetes, but they are being used more and more to help obese and overweight patients lose weight
Silvana Obici, medical director of the Stony Brook Diabetes Center, said, "The risk of developing NAION so far is reported to be low, possibly well below 0.1 % over many years of follow-up." Obici, who is also the chief of the Division of Endocrinology at Stony Brook Medicine, said non-arteritic anterior ischemic optic neuropathy is more common in people who are older, have diabetes or cardiovascular and cerebrovascular disease
In clinical trials, 3% of Wegovy participants reported hair loss compared to 1% on placebo
It gets skipped constantly
Gastric sleeve and gastric bypass are two common weight-loss surgeries
Contact us if youd like to request reuse of a visual asset